Marty Visits 4 - 5: Clinical Challenges in the Management of Schizophrenia-A 22-year-old man with schizophrenia


Marty Visits 4 - 5: Clinical Challenges in the Management of Schizophrenia-A 22-year-old man with schizophrenia

Topic: Psychiatry
Relevant Terms: Patient Adherence, Patient Compliance, Schizophrenia, Psychosis, Antipsychotics, Recovery, Remission, Psychotic Disorders, Long-acting Injectables
Primary Audience: The intended audience for this activity is psychiatrists and other healthcare professionals who treat patients with schizophrenia. Estimated time to complete this activity=30 minutes.
Launch Date: 08-May-14
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Schizophrenia

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe current guidelines for accepted treatment approaches to the maintenance phase of schizophrenia, with a focus on strategies for relapse prevention. 
  2. Address common clinical complications of schizophrenia, including persistent positive [psychotic], negative, and cognitive symptoms.
  3. Integrate effective strategies for improving pharmacologic response in patients with schizophrenia.


    Peter J. Weiden, MD
    Professor of Psychiatry
    University of Illinois Medical Center
    Chicago, IL
    Sean David Conrin, MD
    Assistant Professor of Psychiatry
    Department of Psychiatry
    University of Illinois at Chicago
    Chicago, IL
    Paul P. Doghramji, MD, FAAFP
    Medical Director for Health Services at Ursinus College
    Family Physician, Collegeville Family Practice
    Collegeville, PA
    Randye G. Kaye, BS
    Author/Patient Advocate
    Family-to-Family Trainer
    National Alliance on Mental Illness
    Hartford, CT
    Stephen R. Marder, MD
    Professor of Psychiatry
    Semel Institute for Neuroscience at UCLA
    Director, VISN 22 Mental Illness Research, Education, and Clinical Center
    VA Greater Los Angeles
    Los Angeles, CA
    In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

    Peter J. Weiden, MD
    • Consultant: Deplor, J&J, Genentech/Roche, Lundbeck, Otsuka, Novartis, Reckitt Benckiser Pharmaceuticals, and Sunovion
    • Speaker Bureau: J&J, Genentech/Roche, Lundbeck, Otsuka, Novartis, and Sunovion
    • Research Support: Genentech/Roche, Neurocrine, and Novartis
    Sean David Conrin, MD
    • Dr. Conrin has disclosed no relevant financial relationships.
    Paul P. Doghramji, MD, FAAFP
    • Speaker Bureau: Takeda, Horizon, and Teva
    • Advisory Board: UCB Pharma and Teva
    Randye G. Kaye, BS
    • Speaker/Consultant: Sunovion Pharmaceuticals and Jazz Pharmaceuticals
    Stephen R. Marder, MD
    • Consulting Fees: Abbott, Genentech, Roche, Lundbeck, Boehringer Ingelheim, Pfizer, Shire, Targacept, and EnVivo
    • Research Support: Sunovion, Amgen, and Genentech
    The information presented at this activity is provided for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, Penn State College of Medicine, and Otsuka American Pharmaceutical, Inc. do not recommend the use of any agent outside the labeled indications.
    The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, Penn State College of Medicine, and Otsuka American Pharmaceutical, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Penn State Hershey College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity is co-sponsored by Curatio CME Institute.
    Information about CME credit for this activity is available by contacting Penn State at (717) 531-6483 or Reference course #G5400C-14T
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA category 1 credit™. A statement of credit will be available to print from your user history page.
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 65% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    Supported Browsers
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 5.0+ for Mac OSX 10.5 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above


    Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck